Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Time to Loss of Consciousness With Remimazolam Versus Propofol for Anesthetic Induction in Laparoscopic Cholecystectomy (REMIPROP-LOC)

15 luglio 2026 aggiornato da: Fabrício Dias Antunes, Universidade Federal de Sergipe

Time to Loss of Consciousness With Remimazolam Versus Propofol During Anesthetic Induction for Laparoscopic Cholecystectomy: A Single-Center Randomized Controlled Trial

The goal of this clinical trial is to compare two medicines used to induce general anesthesia in adults undergoing elective laparoscopic cholecystectomy. The study aims to determine whether remimazolam leads to a different time to loss of consciousness than propofol.

The main question it aims to answer is: Does remimazolam change the time to loss of consciousness compared with propofol during anesthesia induction?

Researchers will compare remimazolam with propofol to evaluate the time required for participants to lose consciousness. The study will also compare blood pressure, heart rate, and other safety outcomes during anesthesia induction.

Participants will:

  • Be randomly assigned to receive either remimazolam or propofol for anesthesia induction.
  • Receive standard monitoring and anesthesia care throughout surgery.
  • Have their time to loss of consciousness, vital signs, and any adverse events recorded during the induction period.

Panoramica dello studio

Stato

Non ancora reclutamento

Condizioni

Intervento / Trattamento

Descrizione dettagliata

General anesthesia can be induced with several intravenous hypnotic agents. Propofol remains a standard choice due to its rapid onset and predictable clinical effect; however, it is frequently associated with dose-dependent cardiovascular depression. Remimazolam, an ultra-short-acting benzodiazepine, represents an alternative with a distinct metabolic pathway via tissue esterases, potentially offering greater hemodynamic stability. Nonetheless, current literature comparing induction kinetics between these two pharmacological strategies exhibits high heterogeneity, often driven by variations in drug delivery methods and mixed surgical profiles.

To improve the internal validity of these clinical comparisons, this protocol restricts the evaluation to a single, specific surgical model. Narrowing the clinical environment to a uniform surgical procedure eliminates major confounding variables-such as widely divergent operational durations, patient positioning dynamics, unexpected blood loss, and varying baseline nociceptive stimuli-which typically complicate broader, multi-procedural anesthesia trials.

Furthermore, because the physical characteristics of the study medications preclude complete investigator masking during drug administration, specific operational safeguards are built into the clinical workflow. Anesthesia delivery during the induction phase relies entirely on pre-specified, automated delivery algorithms (comparing a fixed-rate continuous infusion against a pharmacokinetic target-controlled model) rather than subjective, clinician-guided titration. Utilizing fixed algorithmic delivery protocols prevents clinical preferences from influencing drug administration, thereby controlling for potential execution bias.

Following the induction phase, physiological tracking and depth-of-anesthesia monitoring are managed through objective, automated indices to ensure that post-induction adjustments remain standardized across both evaluation groups. This structured approach ensures that the resulting clinical observations reflect the distinct pharmacological and pharmacokinetic profiles of the selected hypnotic strategies rather than confounding clinical management choices.

Tipo di studio

Interventistico

Iscrizione (Stimato)

66

Fase

  • Fase 4

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Luoghi di studio

  • Brasile
    • Sergipe
      • Aracaju, Sergipe, Brasile
        • Hospital Univeritário da Universidade Federal de Sergipe
        • Contatto:

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

  • Adulto

Accetta volontari sani

No

Descrizione

Inclusion Criteria:

  • Patients aged 18 years or older.
  • American Society of Anesthesiologists (ASA) physical status I or II.
  • Scheduled to undergo elective laparoscopic cholecystectomy under Total Intravenous Anesthesia (TIVA).

Exclusion Criteria:

  • Patients younger than 18 years or older than 50 years
  • American Society of Anesthesiologists (ASA) physical status III to V
  • Body Mass Index (BMI) < 17.5 kg/m² or > 30 kg/m²
  • Hemodynamically unstable patients
  • Altered or impaired renal or hepatic function
  • Neuromuscular disorders
  • History of alcohol or drug dependence
  • History of allergy or hypersensitivity to any of the anesthetic medications utilized in the protocol

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Separare

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Remimazolam
Patients will receive intravenous remimazolam for both the induction and maintenance of general anesthesia. Anesthesia induction will be initiated via continuous intravenous infusion at a fixed rate of 6 mg/kg/h until loss of consciousness is achieved. Following induction, anesthesia maintenance will be transitioned to a continuous intravenous infusion of remimazolam at a baseline rate of 1 mg/kg/h, which will be titrated dynamically to maintain objective depth-of-anesthesia monitoring using a bispectral index (BIS) target value between 40 and 60 until the end of the surgical procedure.
Droga: Remimazolam
Lyophilized powder reconstituted for intravenous injection. Administered via an electronic infusion pump at a fixed continuous induction rate of 6 mg/kg/h until clinical benchmarks are achieved. Maintenance is sustained at a baseline continuous infusion rate of 1 mg/kg/h. To ensure a strictly standardized anesthetic baseline, all patients receive a uniform, weight-based co-administration of intravenous fentanyl and a neuromuscular blocking agent at induction, followed by a continuous intraoperative analgesic infusion of remifentanil via target-controlled infusion (TCI) guided by the Minto model (effect-site targeting). Maintenance remimazolam doses are precisely titrated based on real-time bispectral index (BIS) values to target a depth of anesthesia between 40 and 60.
Comparatore attivo: Propofol
Patients will receive intravenous propofol for both the induction and maintenance of general anesthesia. Anesthesia induction will be performed using a target-controlled infusion (TCI) model with a fixed target concentration of 4 mcg/mL until loss of consciousness is achieved. Following induction, anesthesia maintenance will be continued via propofol infusion, titrated dynamically to maintain objective depth-of-anesthesia monitoring using a bispectral index (BIS) target value between 40 and 60 until the end of the surgical procedure.
Droga: Propofol
Intravenous 1% lipid emulsion formulation of propofol. Administered via an automated target-controlled infusion (TCI) system programmed with the Marsh pharmacokinetic model. Induction is initiated at a fixed effect-site target concentration of 4 mcg/mL. To ensure a strictly standardized anesthetic baseline, all patients receive a uniform, weight-based co-administration of intravenous fentanyl and a neuromuscular blocking agent at induction, followed by a continuous intraoperative analgesic infusion of remifentanil via target-controlled infusion (TCI) guided by the Minto model (effect-site targeting). Maintenance propofol infusion rates are dynamically adjusted to maintain an objective bispectral index (BIS) within the 40-60 range.

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Time to Loss of Consciousness (TLOC)
Lasso di tempo: From the initiation of the hypnotic agent infusion until the achievement of loss of consciousness (estimated time frame of up to 5 minutes during the anesthesia induction phase).
The duration, measured in seconds, from the exact initiation of the intravenous hypnotic agent infusion (either remimazolam or propofol) until the participant achieves clinical loss of consciousness. Loss of consciousness is strictly defined as the co-occurrence of two clinical criteria: the complete loss of response to a standardized verbal command (calling the patient's name aloud) and the absence of the eyelash/palpebral reflex (córneo-palpebral reflex), assessed continuously during the anesthesia induction phase.
From the initiation of the hypnotic agent infusion until the achievement of loss of consciousness (estimated time frame of up to 5 minutes during the anesthesia induction phase).

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Incidence of Anesthesia-Induced Hypotension
Lasso di tempo: From the exact initiation of anesthetic induction until the completion of the surgical procedure (estimated up to 2 hours).
Percentage of participants experiencing at least one episode of hypotension. Hypotension is operationally defined as a decrease in blood pressure of more than 20% from the participant's documented baseline value, or a mean arterial pressure (MAP) lower than 65 mmHg.
From the exact initiation of anesthetic induction until the completion of the surgical procedure (estimated up to 2 hours).
Incidence of Perioperative Adverse Events
Lasso di tempo: From the initiation of anesthetic induction until 1 hour after arrival at the Post-Anesthesia Care Unit (PACU)
Proportion of participants experiencing specific anesthesia-related adverse events, including bradycardia (heart rate < 50bpm), episodes of apnea within the Post-Anesthesia Care Unit (PACU), or any clinical event requiring unplanned therapeutic interventions.
From the initiation of anesthetic induction until 1 hour after arrival at the Post-Anesthesia Care Unit (PACU)
Incidence of Early Postoperative Delirium
Lasso di tempo: Within 1 hour after arrival at the Post-Anesthesia Care Unit (PACU).
Percentage of participants with delirium at discharge from the Post-Anesthesia Care Unit (PACU), assessed using the 4AT (4 A's Test), a validated rapid screening tool for delirium.
Within 1 hour after arrival at the Post-Anesthesia Care Unit (PACU).
Bispectral Index (BIS) Values at Key Anesthetic Milestones
Lasso di tempo: From initiation of anesthetic induction through the intraoperative period (estimated up to 2 hours).
Objective tracking of depth of anesthesia using bispectral index (BIS) values (measured on a scale from 0 to 100, where 100 indicates fully awake and 0 indicates flat-line EEG). Continuous values will be extracted and compared at specific clinical time points: at the initiation of induction, during laryngoscopy, and periodically throughout the intraoperative period.
From initiation of anesthetic induction through the intraoperative period (estimated up to 2 hours).
Time to Tracheal Extubation
Lasso di tempo: From the cessation of anesthetic maintenance until tracheal extubation (estimated up to 20 minutes).
The duration, measured in minutes, from the exact clinical cessation of the maintenance hypnotic delivery (propofol or remimazolam) and the remifentanil infusion until the safe and successful removal of the endotracheal tube.
From the cessation of anesthetic maintenance until tracheal extubation (estimated up to 20 minutes).
Incidence of Postoperative Pain Requiring Opioid Rescue
Lasso di tempo: Within 1 hour after arrival at the Post-Anesthesia Care Unit (PACU).
Percentage of participants experiencing acute postoperative pain that necessitates the administration of supplemental opioid rescue analgesia as part of their recovery management.
Within 1 hour after arrival at the Post-Anesthesia Care Unit (PACU).
Incidence of Postoperative Nausea and Vomiting (PONV)
Lasso di tempo: Within 1 hour after arrival at the Post-Anesthesia Care Unit (PACU).
Percentage of participants experiencing episodes of nausea, vomiting, or retching during the immediate recovery phase.
Within 1 hour after arrival at the Post-Anesthesia Care Unit (PACU).

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Universidade Federal de Sergipe

Collaboratori

Cristália Produtos Químicos Farmacêuticos Ltda.

Investigatori

  • Investigatore principale: Fabrício A Dias Antunes, MD, MSc, PhD, Universidade Federal de Sergipe

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Stimato)

1 agosto 2026

Completamento primario (Stimato)

1 giugno 2027

Completamento dello studio (Stimato)

1 giugno 2027

Date di iscrizione allo studio

Primo inviato

8 luglio 2026

Primo inviato che soddisfa i criteri di controllo qualità

15 luglio 2026

Primo Inserito (Effettivo)

21 luglio 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

21 luglio 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

15 luglio 2026

Ultimo verificato

1 luglio 2026

Maggiori informazioni

Termini relativi a questo studio

Parole chiave

Termini MeSH pertinenti aggiuntivi

Altri numeri di identificazione dello studio

  • 97389426.1.0000.5546

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

SÌ

Descrizione del piano IPD

Individual participant data (IPD) underlying the published results will be shared upon reasonable request after publication of the main findings. All shared data will be fully de-identified to protect participant privacy. Access will be granted to qualified researchers whose proposed use is methodologically sound and ethically appropriate. Data will be provided through a controlled process and only for research purposes aligned with the objectives of the study.

Periodo di condivisione IPD

IPD and supporting documents will be available beginning 12 months after publication of the primary results and will remain available for at least 5 years thereafter.

Criteri di accesso alla condivisione IPD

Access to de-identified IPD and supporting documents will be granted upon reasonable request to qualified researchers. Requests must include a methodologically sound proposal and a commitment to use the data only for research purposes aligned with ethical and scientific standards. Data will be shared through a controlled process after approval by the study team.

Tipo di informazioni di supporto alla condivisione IPD

  • STUDIO_PROTOCOLLO
  • LINFA

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Prove cliniche su Remimazolam

Cerca prove simili

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

CROs by country

CROs in Guinea

Condizioni

Malattie rare

Interventi farmacologici

Supplementi dietetici

Sponsor / Collaboratori

Sedi

3
Sottoscrivi